Leqembi, which was approved in 2023 to treat the mind-robbing disease, generated $168 million in sales, up 74 percent from ...
Multiple system atrophy (MSA) is an adult-onset, rapidly progressive neurodegenerative disorder characterised by the aggregation of α-synuclein in oligodendroglial cytoplasmatic inclusions.1 ...
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports ...
MELBOURNE, Australia and SAN FRANCISCO, April 15, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity” or "the Company”), a biotechnology company dedicated to developing ...
Plant owners and operators are always trying to do more with less, but finding solutions to the problems currently impacting manufacturing environments isn’t so simple. The reason is that ...
Cenrifki prevents MS disease progression and Itvisma delivers a healthy gene-to-cell nuclei, addressing the root cause of SMA.
Hosted on MSN
Understanding ataxia from genes to daily life
Ataxia is more than just clumsiness—it’s a neurological condition that affects coordination, balance, speech, and even vision ...
Galmed Pharmaceuticals Ltd. (Galmed), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced the breakthrough development of a brain ...
98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS). Galmed has developed, in collaboration with Barcode ...
Hosted on MSN
Understanding ataxia and its many faces
Ataxia isn’t a single disease but a group of movement disorders that affect balance, coordination, and speech. It can be inherited, acquired, or linked to other neurological conditions, making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results